Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
 | AB INBEV | - | 30 | +0,10 % | |
| ARGENX | - | 10 | -0,36 % | ||
| MELEXIS | - | 4 | -0,30 % | |
| ELIA GROUP | - | 4 | +0,49 % | |
| UMICORE | - | 2 | -0,44 % | |
| AGEAS | - | 1 | -0,27 % | |
| KBC GROEP NV | - | 1 | +0,31 % | |
| GBL | - | 1 | +0,14 % | |
| MONTEA | - | 1 | -0,93 % | |
| AEDIFICA | - | 1 | +0,38 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Umicore - Transparency notifications by BlackRock, Inc. | 14 | GlobeNewswire (USA) | ||
| Fr | Aedifica NV/SA: Publication relating to a transparency notification | 1 | GlobeNewswire (USA) | ||
| Fr | Solvay and Veolia accelerate towards a circular industry with recycling unit | 3 | Hydrocarbon Engineering | ||
| Fr | Data at EULAR back Biogen, UCB's first-in-class lupus drug | 5 | pharmaphorum | ||
| Fr | UCB To Invest In U.S. Biologics Facility With $5 Bln Economic Impact | 5 | RTTNews | ||
| Do | UCB touts plan for 'major' US investment to boost biologics capacity | 3 | FiercePharma | ||
| Do | Dividendenbekanntmachungen (12.06.2025) | 6.205 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADT INC US00090Q1031 0,055 USD 0,0478 EUR ALAMOS GOLD INC CA0115321089 0,0342 CAD 0,0218 EUR ALIBABA GROUP HOLDING LTD ADR US01609W1027 1... ► Artikel lesen | |
| Do | ANHEUSER-BUSCH INBEV SA/NV - AB InBev Announces Final Results of Cash Tender Offers for up to USD 2 Billion Aggregate Purchase Price | 14 | SENS | ||
| Do | Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results | 8 | Benzinga.com | ||
| Do | UCB & Biogen: Phase 3 Trial Of Dapirolizumab Pegol In Systemic Lupus Erythematosus Meets Main Goal | 257 | AFX News | WESTON (dpa-AFX) - UCB (UCB) and Biogen Inc. (BIIB) presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L... ► Artikel lesen | |
| Do | UCB: BIMZELX 3-Year Results Confirm Sustained Efficacy In Psoriatic And Axial Spondyloarthritis | 2 | RTTNews | ||
| Mi | UCB: BIMZELX (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis | 88 | PR Newswire | Sustained symptom relief in patients with psoriatic arthritis: Achievement of the stringent ACR50 endpoint was sustained at three years by 53.2% and 55.2% of patients... ► Artikel lesen | |
| Mi | Argenx stock price target reiterated at $761 on positive trial data | 6 | Investing.com | ||
| Mi | Argenx-Kursziel von 761 US-Dollar nach positiven Studiendaten bestätigt | 15 | Investing.com Deutsch | ||
| Mi | Drei Konzerne brauen fast die Hälfte des Biers - AB Inbev an der Spitze | 473 | dpa-AFX | NÜRNBERG (dpa-AFX) - Drei Großkonzerne brauen fast die Hälfte des weltweit verkauften Biers. Im vergangenen Jahr ist die weltweite Produktion der größten vierzig Brauereigruppen nach Berechnung des... ► Artikel lesen | |
| Mi | UCB's Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials | 3 | PMLiVE | ||
| Mi | ARGENX SE - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Mi | Aedifica NV/SA: Convocation to the Extraordinary General Meeting of 11 July 2025 | 2 | GlobeNewswire (USA) | ||
| Mi | argenx SE: argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease | 10 | GlobeNewswire (USA) | ||
| Di | GBL: GBL - Transactions on GBL shares 10-06-2025 | 2 | Euronext |
1 2 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .